Tarsus Pharmaceuticals (TARS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

Continuing to advance the pipeline and remain on-track to engage with the FDA on TP-04 (Papulopustular Rosacea) and TP-05 ...

XDEMVY (lotilaner ophthalmic solution) 0.25%, formerly known as TP-03, is a novel prescription eye drop designed to treat Demodex blepharitis by targeting and eradicating the root cause of the disease ...

In the fourth full quarter of our launch, we generated more than $48 million in XDEMVY net product sales driven by more than 41,000 bottles delivered to patients impacted by demodex blepharitis or DB.

Humana CMO brings more than two decades of experience driving innovative, value-based initiatives designed to improve patient outcomesIRVINE, ...

The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex ...

Eyelash extensions have become a popular beauty treatment, but could they be putting your eye health at risk? Health ...

Detailed price information for Tarsus Pharmaceuticals Inc (TARS-Q) from The Globe and Mail including charting and trades.